Emgality^®: a migraine treatment that can fit into your patient’s life¹

Learn more about migraine below, including its impact on your patients, and current treatment guidelines

Who is appropriate for Emgality?

MEET JESSICA^a

AGE: 38

CLINICAL FACTORS

4 or more unpredictable migraine headache days (MHDs) per month
Has tried therapeutic doses of 2 standard-of-care generic preventives
May now be only relying on her acute treatments

NON-CLINICAL FACTORS

Isn’t sure another preventive will give her the results she is looking for

^aHypothetical patient profile.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Migraine can have a profound impact on people’s lives^2,3

More than 30 million adults are living with migraine in the United States^2,4,5

Migraine may affect productivity at work¹

Nearly 30% of people with migraine reported that their productivity at work was reduced by at least 50% in the previous 3 months in the American Migraine Prevalence and Prevention (AMPP) study^a

^aThe AMPP study surveyed households to identify people with migraine.¹

Migraine may affect productivity at home^2,3

85% of people reported substantial reductions in their ability to do household work or chores due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study

More than one-third of people with migraine reported that household productivity was reduced by at least 50% in the previous 3 months in the AMPP study

Migraine may affect leisure time and activities³

45% of people reported missing family, social, and leisure activities due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study

Migraine can lead to reduced productivity and cost people valuable time for work, household tasks, and leisure^2,3

The Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive (RF-R) domain is a self-administered tool designed to assess the functional impact of migraine on daily activities.⁶

Read more about the MSQ v2.1 on Efficacy—Episodic Migraine.

In a global patient survey, approximately 4 out of 10 patients who took an oral migraine preventive, including standard-of-care treatments, discontinued due to side effects or lack of efficacy^7,8a

Preventive medication use and reasons for discontinuation were collected in an international Web-based, cross-sectional survey of adults with migraine during 2010. Among respondents who reported prior use of oral preventive medications, satisfactory resolution, lack of efficacy, side effects, cost, or other could be selected as the reason for discontinuation.

Surveys were completed by 98.5% (n=1165) of eligible responders. Surveyed eligible responders were classified as episodic migraine (n=672, 57.7%) or chronic migraine (n=493, 42.3%).

Comparable real-world data do not exist for Emgality.

Patient-reported reasons for discontinuation of preventive medications

^aOral migraine preventive categories included antidepressants, antiepileptics, beta-blockers, and calcium channel blockers.⁷

Migraine medications commonly used for prevention⁹

Many of the medications commonly used for migraine prevention are not classified as Level A or Level B preventive therapies by the American Academy of Neurology (AAN) and the American Headache Society (AHS)⁸

View 2^nd and 4^th month refill rate equivalent data for select preventive migraine medications

American Headache Society (AHS) indications for initiating treatment with CGRP antibodies¹⁰

Migraine preventives can only be prescribed by a licensed medical provider^a and the patient must be at least 18 years old. Patients must meet the appropriate criteria for one of the conditions listed below¹⁰

The American Headache Society recommends initiating treatment with CGRP antibodies for adult patients who experience¹⁰:

Migraine with or without aura (4-7 monthly headache days) and both of the following:

Inability to tolerate at least 2 prior preventive treatments due to side effects OR inadequate response to a 6-week trial of at least 2 prior preventive treatments AND

At least moderate patient-reported disability^b

Migraine with or without aura (8-14 monthly headache days) and:

Inability to tolerate at least 2 prior preventive treatments due to side effects OR inadequate response to a 6-week trial of at least 2 preventive treatments

Chronic migraine and either of the following:

Inability to tolerate at least 2 prior preventive treatments due to side effects OR inadequate response to a 6-week trial of at least 2 prior preventive treatments OR

Inability to tolerate or inadequate response to a minimum of 2 quarterly injections (6months) of onabotulinumtoxinA

^aDoctor of medicine, doctor of osteopathy, advanced practice provider (DDS [Doctor of Dental Surgery] or DMD [Doctor of Medicine in Dentistry or Doctor of Dental Medicine]).

^bDisability can be measured according to the Migraine Disability Assessment (MIDAS) or Headache Impact Test-6 (HIT-6). Moderate disability was considered MIDAS>11 or HIT-6>50.

Calcitonin gene-related peptide (CGRP) is thought to play a central role in migraine pathogenesis¹¹

Elevated levels of CGRP can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP¹¹

CGRP, released from the trigeminal ganglia, is elevated during migraine attacks¹¹
Perivascular release of CGRP has been shown to induce vasodilation and plasma protein leakage from tissues¹¹
An infusion of CGRP can induce migraine attacks in susceptible individuals, and CGRP is involved in the transmission of pain^12,13

Learn about how a CGRP antibody works

The Migraine: Patient Questionnaire can help inform your treatment plan

The questionnaire is an impact assessment that helps you uncover the burden migraine is placing on your patients’ lives. This understanding can assist you in determining a treatment plan that may be right for your patients.

Download or contact a representative for copies of the Migraine: Patient Questionnaire.

Learn more about a treatment that can help patients like Jessica

Emgality has been studied in patients with episodic migraine, chronic migraine, episodic cluster headache, and in a 12-month, open-label safety study^1,14

Learn more about episodic migraine, chronic migraine, episodic cluster headache, or a 12-month, open-label safety study

Safety across five Phase 3 studies in patients with migraine^1,14-19

Learn more about safety

As of 1/4/2020, best-in-class^a commercial access for the preventive treatment of migraine^1,20

^aBest-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine. Does not take into consideration any restrictions set forth by individual plans. Data as of 1/2021.

Source: Managed Markets Insight & Technology (MMIT), LLC as of 1/2021 and is subject to change without notice. Please contact the plan or state for the most current information. “Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employers and employer groups may also offer additional benefit designs, which may be different than described.

Learn more about coverage for your patients

Emgality comes in an easy-to-use pen for self-administration^1,21

Patient- and caregiver-rated experiences with the pen were assessed in an open-label, 12- month study. A total of 84 patients who received once-monthly injections of Emgality 120mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use.²²

Learn more about dosing

“Even though I try to stay positive and push through, migraine continues to impact my work and my personal life. It’s important to me to find a treatment regimen that fits into my life because my family depends on me.”

— Jessica, hypothetical patient with episodic migraine

We interviewed 4 real patients on Emgality to learn how taking a migraine preventive has impacted their lives. Watch their stories here.

^bPatients were compensated for their time.

INDICATION
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Download savings cards for your patients^c

^cGovernmental beneficiaries excluded. Terms and Conditions apply.

References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Lipton RB, Bigal ME, Diamond M, et al; for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349. 3. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23:429-440. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0028. 5. US Census Bureau. Quick facts. https://www.census.gov/quickfacts/fact/table/US/PST045217. Accessed November 9, 2020. 6. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421. 7. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS - II) Headache. 2013;53:644-655. 8. Silberstein SD, Holland S, Freitag F, et al. Correction: Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80:871. 9. Data on File. Lilly USA, LLC. DOF-GZ-US-0109. 10. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18. 11. Durham PL. CGRP-receptor antagonists—A fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073-1075. 12. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54-61. 13. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403:350-354. 14. Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2. 15. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. 16. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 17. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. 18. Data on File. Lilly USA, LLC. DOF-GZ-US-0107. 19. Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90.doi:10.1186/s12883-020-1609-7. 20. Data on File. Lilly USA, LLC. DOF-GZ-US-0111. 21. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 22. Data on File. Lilly USA, LLC. DOF-GZ-US-0020.

Ask Lilly your questions!
We’re here to help.

Emgality^®: a migraine treatment that can fit into your patient’s life¹

Learn more about migraine below, including its impact on your patients, and current treatment guidelines

Who is appropriate for Emgality?

Migraine can have a profound impact on people’s lives^2,3

More than 30 million adults are living with migraine in the United States^2,4,5

Migraine can lead to reduced productivity and cost people valuable time for work, household tasks, and leisure^2,3

In a global patient survey, approximately 4 out of 10 patients who took an oral migraine preventive, including standard-of-care treatments, discontinued due to side effects or lack of efficacy^7,8a

Migraine medications commonly used for prevention⁹

Many of the medications commonly used for migraine prevention are not classified as Level A or Level B preventive therapies by the American Academy of Neurology (AAN) and the American Headache Society (AHS)⁸

View 2^nd and 4^th month refill rate equivalent data for select preventive migraine medications

American Headache Society (AHS) indications for initiating treatment with CGRP antibodies¹⁰

Migraine preventives can only be prescribed by a licensed medical provider^a and the patient must be at least 18 years old. Patients must meet the appropriate criteria for one of the conditions listed below¹⁰

Calcitonin gene-related peptide (CGRP) is thought to play a central role in migraine pathogenesis¹¹

Elevated levels of CGRP can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP¹¹

Learn about how a CGRP antibody works

The Migraine: Patient Questionnaire can help inform your treatment plan

Download or contact a representative for copies of the Migraine: Patient Questionnaire.

Learn more about a treatment that can help patients like Jessica

Emgality has been studied in patients with episodic migraine, chronic migraine, episodic cluster headache, and in a 12-month, open-label safety study^1,14

Safety across five Phase 3 studies in patients with migraine^1,14-19

As of 1/4/2020, best-in-class^a commercial access for the preventive treatment of migraine^1,20

Emgality comes in an easy-to-use pen for self-administration^1,21

“Even though I try to stay positive and push through, migraine continues to impact my work and my personal life. It’s important to me to find a treatment regimen that fits into my life because my family depends on me.”

— Jessica, hypothetical patient with episodic migraine

We interviewed 4 real patients on Emgality to learn how taking a migraine preventive has impacted their lives. Watch their stories here.

Indications

Important Safety Information

Emgality®: a migraine treatment that can fit into your patient’s life1

Learn more about migraine below, including its impact on your patients, and current treatment guidelines

Who is appropriate for Emgality?

Indications

Important Safety Information

Are you a US healthcare provider?

You are now leaving Emgality.com.

Are you a US healthcare provider?

Terms and Conditions:

Emgality^®: a migraine treatment that can fit into your patient’s life¹